A Shared Bond, a Love for the Game
By Doug Segrest | May 16, 2025
Two days ago, Lulu Gribbin was a participant in the Regions Tradition's celebrity pro-am. As SEC football and basketball coaches arrived at the 17th tee, they wanted to share a moment with the Mountain Brook teenager, who showed off her driving abilities with each new foursome.
Friday, Lulu was back at Greystone Golf and Country Club, this time on the driving range as part of the annual adaptive golf clinic.
A few feet away, Noah Galloway watched as Lulu shared her love of golf with others. They might not have known how much the two of them already share.
Eleven months ago, Lulu and her family were vacationing at the beach when a shark attacked three youths diving for sand dollars. Lulu suffered the most extensive injuries, losing a hand and part of her opposite leg.
Twenty years ago, while serving in the U.S. Army during the Iraq War, Galloway lost his left arm and left leg in battle. Inspired by his own father's struggles after losing a limb in an accident, Galloway now focuses on others.
And when he learned of Lulu's plight, Galloway reached out to her father, Joe Gribbin – first with a text, and then phone calls. They only met in person a week ago.
'I told him I was there and if you ever need something, advice or anything, just call,' Galloway said. 'Because the most important thing is mental health.
'I told her dad, 'Look, the body will adapt. We all have that ability. What we struggle with as humans is our complex brain. It can hold us back and sometimes making sure we take care of that is the most important thing.'
Galloway has gained national acclaim since his recovery. He's a motivational speaker, he works closely with wounded warriors, and he's been a frequent guest on network television. He's also written a book, 'Living with No Excuses: The Remarkable Rebirth of an American Soldier.'
Helping others is the reason Regions, United Ability and the Champions Tour annually hold the adaptive golf clinic. Friday's event featured more than a dozen golfers receiving guidance from local golf pros and volunteers.
Schiela Peña, Disability Services and Outreach manager at Regions, was there to see the magic happen.
'It's so rewarding to have people willing to come alongside you, to teach you that you can go beyond the limits of what people expect you to do,' Peña said.
Adaptive golf is a way to level the playing field and to make activity accessible.
'I think having Lulu here is amazing,' Peña said. 'She's found a way not only to overcome obstacles, but she's made it a point to share her story and motivate others.'
Lulu's father, Joe, pointed out that the recovery was not hers alone. Sister Ellie was with her in the water and witnessed the shark attack and the trauma as Lulu underwent life-saving surgery.
'There's some special trauma, therapy and different classes that helped them do it together,' Joe said. 'Nobody wants to be in this situation. But I feel like Lulu knows she's lucky to be alive. She's handled everything with grace and a very positive attitude.'
Visit 3BL Media to see more multimedia and stories from Regions Bank
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Vikings, OC Wes Phillips agree to contract extension
The Minnesota Vikings will keep Wes Phillips as their offensive coordinator for a little while longer. According to Ben Goessling of the Minnesota Star Tribune, the Vikings and Phillips have agreed to a contract extension. Phillips' deal was set to expire after the 2025 season, but the team is adding one more year to his contract, keeping him on the coaching staff through 2026. Advertisement Phillips joined the Vikings as their offensive coordinator in 2022 after three years with the Los Angeles Rams on Sean McVay's staff. Before that, he was Washington's tight ends coach from 2014-2018, spending three years on the same staff as McVay and two years with Kevin O'Connell. The Vikings have ranked seventh, 10th and 12th in total yards under Phillips the last three years but will look to improve those numbers in 2025 with J.J. McCarthy taking over as the starting quarterback. This article originally appeared on Vikings Wire: Vikings, OC Wes Phillips agree to contract extension
Yahoo
37 minutes ago
- Yahoo
Glenwood softball wins sectional championship
CHATHAM, Ill. (WCIA) – Glenwood softball is one step closer to state after a Friday night win. The Titans, on their home turf, beat Rochester 5-1 to win a 3A sectional championship. Glenwood will now play Centralia in Decatur on Monday, June 9 in Decatur. The winner of Monday's Super-Sectional contest will advance to the state semifinals in Peoria. Advertisement WCIA will have highlights and postgame interviews from the Titans' sectional title win in Friday's 10 p.m. newscast. This story will be updated with video after it airs. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. For the latest news, weather, sports, and streaming video, head to
Health Line
37 minutes ago
- Health Line
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration reportedly plans to cut almost all funding for HIV vaccine research. Experts say the decision comes at a time when research in this field is making substantial progress. Many effective treatments are available for HIV, but these are lifelong commitments that manage a chronic disease rather than cure it. Treatments for HIV infection have come a long way since the 1980s, when too many lives were lost during the epidemic. Today, antiretroviral therapies and other treatments allow people with HIV to live longer lives and, in many cases, prevent the transmission of the virus that causes the disease to other people. Scientists now say the next step in the fight is a vaccine that protects against HIV. However, that next development could be on the chopping block. Trump administration officials reportedly plan to halt funding for a wide array of HIV vaccine research. Researchers told CBS News they have been informed by officials at the National Institutes of Health (NIH) that the Department of Health and Human Services (HHS) has instructed the agency not to issue any more funding during the next fiscal year for HIV vaccine research. NIH officials said HHS officials have instead decided to 'go with currently available approaches to eliminate HIV.' The decision will close down HIV vaccine research projects at the Duke Human Vaccine Institute and the Scripps Research Institute, according to a report in the journal Science. Officials at Moderna also told CBS News that their current clinical trials on HIV vaccines have been put on hold. Experts say the decision to cut funding for an HIV vaccine is short-sighted and reckless. 'I'm stunned by this decision,' said Jake Scott, MD, a clinical associate professor of medicine at Stanford University in California who specializes in infectious diseases. 'There is no scientific or medical evidence to justify these cuts at the exact moment this field is showing real promise,' he told Healthline. Carl Baloney Jr., the chief executive officer-elect of AIDS United, agreed. 'Eliminating funding for HIV vaccine research undermines decades of scientific progress and turns our back on a future where HIV could be preventable for all, regardless of where someone lives, their income, or access to healthcare,' he told Healthline. Why an HIV vaccine is important Experts say that treatments for HIV are incredibly effective. However, they note that most involve daily adherence and aren't necessarily readily available or affordable for many people. 'There are a lot of good options, but they can be really expensive,' Scott said. 'These medications are also not a cure. They are a lifetime burden.' The experts add that people with low levels of HIV in their system can still have weakened immune systems. That can raise the risk of serious infections as well as inflammation that can lead to conditions such as heart disease. 'A vaccine can help prevent all this,' said Scott. Experts note that a vaccine research program may be difficult to put back together even if a new administration restored funding in the near future. They say it took decades to build these programs and restarting them would take time. In addition, researchers will leave the field of HIV prevention to set up shop in another industry that is receiving funding. 'We could lose an entire generation of scientists,' said Scott. 'This is setting the field back a decade or more at a critical time.' 'This isn't just about canceling [a] clinical trial. It's about sidelining the scientists, institutions, and community partners driving innovation forward,' added Baloney. 'These setbacks could delay the development of a successful HIV vaccine by years or even decades.' How scientists fought against HIV The first treatment for HIV was approved by the Food and Drug Administration (FDA) in 1987. Azidothymidine (AZT) was first developed in 1964 as a treatment for cancer. It was ineffective in that usage, but in the 1980s, scientists discovered AZT could suppress HIV replication without damaging healthy cells. It helped treat people with AIDS as well as people who were HIV positive but had no symptoms. In the 1990s, other nucleoside reverse transcriptase inhibitors (NRTIs) were developed and approved. Laboratory tests to measure viral load and cell counts accelerated this research. From there, scientists experimented with combining drugs to help counter the HIV virus's ability to mutate and replicate. In 1996, a triple-drug therapy proved effective in thwarting HIV replication and creating a barrier against drug resistance. Since then, these antiretroviral drugs have become more effective and more available. The effectiveness of these medications is nothing short of miraculous. In the 1980s, the average life expectancy after an AIDS diagnosis was one year. Today, people who adhere to combination antiretroviral drug therapies can expect to live a near-normal life span. In some cases, the medications can reduce the HIV viral load in a person to the point where the virus is undetectable and can't be transmitted to another person. How is HIV treated today? More than 50 types of HIV medications are now approved for use. Some of the more commonly used antiretroviral medications are: Combination NRTI drugs that include Truvada and Descovy. These medications work by preventing HIV from converting its RNA into DNA. This prevents the virus from making copies of itself.. Integrase strand transfer inhibitors (INSTIs) that include Vocabria and Biktarvy. These drugs work by blocking an enzyme that HIV uses to put HIV DNA into human DNA inside cells. Protease inhibitors (PIs) such as Lexiva and Crixivan. These medications work by blocking an enzyme that HIV needs as part of its life cycle. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that include Intelence and Viramune. These drugs work by preventing the HIV virus from making copies of itself. Entry inhibitors such as Fuzeon and Selzentry. These medications work by blocking HIV from entering CD4 T cells. In addition, there are drugs known as Cytochrome P4503A (CYP3A) inhibitors, such as Tybost and Norvir, that help boost the levels of HIV medications in the bloodstream. There are also medications known as post-attachment inhibitors that when used with antiretroviral drugs can help prevent HIV from entering immune cells. Trogarzo was the first of these drugs to become available, having been approved in 2018. In addition, there are attachment inhibitor medications, a newer form of HIV drug that works by attaching to a viral protein, which prevents that protein from entering healthy T cells. Only one type of this medication, Rubokia, is currently available, having been approved in 2020. Most people with HIV are given medications, but there also are long-acting injections that are given once a month or once every other month. Scott said these treatments are cures that have turned HIV into a 'managed chronic disease' to the point where he and other colleagues now refer to AIDS as 'advanced HIV.' Baloney said, however, there are limits to how much treatments can do. 'Current treatments and prevention tools have transformed HIV into a manageable chronic condition, but they are not a cure and they're not accessible to everyone,' he said. 'An HIV vaccine would be a game-changer, especially for communities facing systemic barriers to care.' Preventive measures for HIV Even with the available treatments, experts agree that it's better for a person if they don't contract HIV in the first place. They say condom use, along with dental dams and gloves, can be effective barriers to contracting HIV. Limiting sexual partners is also recommended, as are sterile needles for intravenous drug users. Getting tested for HIV is also an important component. It's estimated that more than 1 million people in the United States have HIV, and 13% of them don't know they have contracted the virus. There are medications available that can be taken as a precaution or after potential exposure to HIV. These drugs include: Preexposure prophylaxis (PrEP): These medications can be taken as a daily pill or a bimonthly injection. The first injectable PrEP drug was Apretude, which was approved by the FDA in 2021. Truvada can also be used as PrEP therapy. These medications help prevent HIV from getting a foothold in the body. Postexposure prophylaxis (PEP) drugs: These are designed to be taken within 72 hours of potential exposure to HIV. It is a pill ingested once a day for 28 days. Lenacapavir: This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on June 19. Experts say all these preventive measures are good practices, but they note that vaccines are still the most effective.
